Asymmetric Prurigo Nodularis after Paralysis: A Case Report

Main Article Content

Justin Chu
Icahn School of Medicine at Mount Sinai

Jordan Genece
Icahn School of Medicine at Mount Sinai

Yasmin Amir
Icahn School of Medicine at Mount Sinai

Mark Lebwohl
Icahn School of Medicine at Mount Sinai

Keywords

Abstract

Abstract not available.

References

1. Hyde JN (1883) A Practical Treatise on Diseases of the Skin, for the Use of Students and Practitioners, 1st edn. Lea & Febiger, Philadelphia.(Hyde 1894)

2. Hammes, S. , Hermann, J. , Roos, S. and Ockenfels, H. (2011), UVB 308‐nm excimer light and bath PUVA: combination therapy is very effective in the treatment of prurigo nodularis. Journal of the European Academy of Dermatology and Venereology, 25: 799-803.

3. Iking, A. , Grundmann, S. , Chatzigeorgakidis, E. , Phan, N. , Klein, D. and Ständer, S. (2013), Prurigo as a symptom of atopic and non‐atopic diseases: aetiological survey in a consecutive cohort of 108 patients. Journal of the European Academy of Dermatology and Venereology, 27: 550-557.

4. Zeidler C, Yosipovitch G, Ständer S. Prurigo Nodularis and Its Management. Dermatol Clin. 2018 Jul;36(3):189–97.

5. Alfadley, A. , Al‐Hawsawi, K. , Thestrup‐Pedersen, K. and Al‐Aboud, K. (2003), Treatment of prurigo nodularis with thalidomide: a case report and review of the literature. International Journal of Dermatology, 42: 372-375.

6. Tan, W. S., & Tey, H. L. (2014). Extensive prurigo nodularis: characterization and etiology. Dermatology, 228(3), 276-280.

Article Sidebar

PDF
Published
Jan 28, 2020
DOI https://doi.org/10.25251/skin.4.1.17

Article Details

How to Cite
[1]
Chu, J., Genece, J., Amir, Y. and Lebwohl, M. 2020. Asymmetric Prurigo Nodularis after Paralysis: A Case Report. SKIN The Journal of Cutaneous Medicine. 4, 1 (Jan. 2020), 94–96. DOI:https://doi.org/10.25251/skin.4.1.17.
Issue
Vol. 4 No. 1 (2020): January Issue & Poster Presentations (2020 Winter Clinical Dermatology Conference®)
Section
Short Communications
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>